Fronto-temporal lobar degeneration (FTLD) is a clinically and pathologically heterogeneous syndrome, characterized by progressive decline in behavior or language associated with degeneration of the frontal and anterior temporal lobes. Three distinct clinical variants of FTLD have been described.

PiB-PET, the most commonly used amyloid-PET tracer, has been shown to distinguish FTLD from AD with higher sensitivity (89% vs 73%) but relatively lower specificity (83% vs 98%) compared with 18 F-FDG-PET. 2 However, it should be noted that although it is relatively rare to have a positive amyloid-PET with a clinical diagnosis of bvFTD, it is ...

2011年12月6日 · Objective: To compare the diagnostic performance of PET with the amyloid ligand Pittsburgh compound B (PiB-PET) to fluorodeoxyglucose (FDG-PET) in discriminating between Alzheimer disease (AD) and frontotemporal lobar degeneration (FTLD). Methods: Patients meeting clinical criteria for AD (n = 62) and FTLD (n = 45) underwent PiB and FDG-PET.

To compare the diagnostic performance of PET with the amyloid ligand Pittsburgh compound B (PiB-PET) to fluorodeoxyglucose (FDG-PET) in discriminating between Alzheimer disease (AD) and frontotemporal lobar degeneration (FTLD). Patients meeting clinical criteria for AD (n = 62) and FTLD (n = 45) underwent PiB and FDG-PET.

2022年8月16日 · 18 F-fluorodeoxyglucose (FDG)-PET indicated hypometabolism in FTLD with different mutations preceded the atrophy on MRI. Identifying molecular imaging biomarkers for familial FTLD is important for the in-vivo assessment of underlying pathophysiological changes with disease progression and future disease-modifying therapy.

metabolism. [18F]FDG PET is currently the most accurate in vivo method for the investigation of regional human brain glucose metabolism in health and disease states. The clinical use of [18F]FDG can be regarded as established for several diagnostic questions in neurology, neurosurgery, and psy-chiatry.

2023年8月26日 · In this chapter, we will discuss: (1) indications of FDG PET in dementia evaluation; (2) image interpretation using statistical mapping technology; (3) pretest probability and referral bias; (4) differential diagnoses of Alzheimer’s disease (AD), frontotemporal dementia (FTD), and Dementia with Lewy bodies (DLB); (5) recognition of subtypes ...

2017年9月1日 · FDG has been shown to differentiate between AD vs FTLD with greater accuracy than clinical assessment [58]. The study presented 6 dementia experts with 45 patients with either pathologically confirmed AD (n = 31) or FTLD (n = 14) and compared their clinical diagnosis to visual interpretation of FDG-PET scans.

The panel agreed on recommending FDG-PET for 14 questions: diagnosing mild cognitive impairment due to Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD) or dementia with Lewy bodies (DLB); diagnosing atypical AD and pseudo-dementia; differentiating between AD and DLB, FTLD or vascular dementia, between DLB and FTLD, and between ...

2011年3月23日 · Patients with clinically diagnosed Alzheimer's disease (AD: n = 21), with frontotemporal lobar degeneration (FTLD: n = 14) and control subjects (n = 13) underwent both [F18]fluorodeoxyglucose positron emission tomography (FDG-PET) scanning and magnetic resonance imaging (MRI), together with clinical and behavioral assessment.